Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Chroma Therapeutics
Extension protocol to the OPAL Study (CHR-2797-038).
Study mimics normal clinical practice; few procedures and visits are therefore mandated by the protocol. Timing of bone marrow assessment is also left at the investigator's discretion.
Age
60–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed, informed consent
Completion of Visit 11 in the OPAL Study (Month 6 Visit)
Investigator's opinion that the subject would benefit from continued therapy with tosedostat.
You may not be if
Any co-existing medical condition that in the Investigator's opinion will substantially increase the risk associated with the subject's participation in the study
Psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of the necessary studies
Administration of any (other) investigational agent within 14 days of entry into TOPAZ.
Clareo Health | Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid Leukemia
